Saturday, September 12, 2009 16:00 IST
Opexa Therapeutics, Inc, a company developing Tovaxin, a personalized T-cell immunotherapy for multiple sclerosis (MS), announced results from further analysis of the double-blind, placebo-controlled, 52-week phase-IIb TERMS clinical study of 150 patients with Relapsing Remitting MS (RRMS). This analysis evaluated patients with an annualized relapse rate of one or greater at study entry (ARR=1). More than 83 per cent of the Tovaxin-treated group (n=85) remained relapse free at one year and the annualized relapse rate after treatment decreased to 0.20, a 42 per cent reduction compared to placebo.
Opexa Therapeutics, Inc, a company developing Tovaxin, a personalized T-cell immunotherapy for multiple sclerosis (MS), announced results from further analysis of the double-blind, placebo-controlled, 52-week phase-IIb TERMS clinical study of 150 patients with Relapsing Remitting MS (RRMS). This analysis evaluated patients with an annualized relapse rate of one or greater at study entry (ARR=1). More than 83 per cent of the Tovaxin-treated group (n=85) remained relapse free at one year and the annualized relapse rate after treatment decreased to 0.20, a 42 per cent reduction compared to placebo.
0 comments:
Post a Comment